- Home
- ECAT vs CERT Comparison
ECAT vs CERT Comparison
Compare ECAT & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECAT
- CERT
- Stock Information
- Founded
- ECAT 2021
- CERT 2008
- Country
- ECAT United States
- CERT United States
- Employees
- ECAT N/A
- CERT N/A
- Industry
- ECAT Trusts Except Educational Religious and Charitable
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- ECAT Finance
- CERT Technology
- Exchange
- ECAT Nasdaq
- CERT Nasdaq
- Market Cap
- ECAT 1.6B
- CERT 1.4B
- IPO Year
- ECAT N/A
- CERT 2020
- Fundamental
- Price
- ECAT $15.90
- CERT $8.35
- Analyst Decision
- ECAT
- CERT Buy
- Analyst Count
- ECAT 0
- CERT 9
- Target Price
- ECAT N/A
- CERT $14.50
- AVG Volume (30 Days)
- ECAT 278.6K
- CERT 2.4M
- Earning Date
- ECAT 01-01-0001
- CERT 11-06-2025
- Dividend Yield
- ECAT 9.20%
- CERT N/A
- EPS Growth
- ECAT N/A
- CERT N/A
- EPS
- ECAT 2.39
- CERT 0.07
- Revenue
- ECAT N/A
- CERT $415,551,000.00
- Revenue This Year
- ECAT N/A
- CERT $11.70
- Revenue Next Year
- ECAT N/A
- CERT $8.03
- P/E Ratio
- ECAT $7.15
- CERT $123.15
- Revenue Growth
- ECAT N/A
- CERT 11.47
- 52 Week Low
- ECAT $14.02
- CERT $8.13
- 52 Week High
- ECAT $17.30
- CERT $15.69
- Technical
- Relative Strength Index (RSI)
- ECAT 38.72
- CERT 23.03
- Support Level
- ECAT $15.81
- CERT $8.14
- Resistance Level
- ECAT $16.51
- CERT $8.91
- Average True Range (ATR)
- ECAT 0.21
- CERT 0.65
- MACD
- ECAT -0.02
- CERT -0.38
- Stochastic Oscillator
- ECAT 17.98
- CERT 4.35
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.